FDA Briefing Document: Ipamorelin-Related Bulk Drug Substances (PCAC October 2024)

FDA recommended against placing ipamorelin free base or ipamorelin acetate on the 503A bulk list due to characterization and safety concerns.

Not legal or medical advice.

This page is for informational purposes only. Always verify the current official source or consult a qualified professional before making compliance, prescribing, purchasing, or clinical decisions. Read full disclaimer.